Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?

Nearly two months after getting the boot from the NIH’s ACTIV-3 study over a failed futility analysis, Novartis and Molecular Partners are back with mid-stage results they say prove their Covid-19 antiviral works better in patients who aren’t hospitalized — and CEO Vas Narasimhan likes what he sees.